✦ LIBER ✦

Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease

✍ Scribed by Iracema Leroi; Jason Brandt; Stephen G. Reich; Constantine G. Lyketsos; Stephen Grill; Richard Thompson; Laura Marsh

Publisher: John Wiley and Sons
Year: 2004
Tongue: English
Weight: 78 KB
Volume: 19
Category: Article
ISSN: 0885-6230
DOI: 10.1002/gps.993

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Objective

To evaluate the efficacy and safety of donepezil, an acetylcholinesterase inhibitor, as a treatment for cognitive impairment and dementia in patients with Parkinson' s disease (PD).

Methods

Using a randomized, double‐blind, placebo‐controlled design, nine patients received placebo and seven patients received donepezil (2.5–10 mg/day) for a mean (SD) duration of 15.2 (3.4) weeks. The primary efficacy outcomes were derived from a neuropsychological battery that assessed global cognitive status as well as memory, attention, psychomotor speed, and visuospatial and executive functions. Secondary efficacy outcomes were psychiatric symptom and activities of daily living ratings. Primary safety measures were motor signs and assessments of adverse effects.

Results

Patients on donepezil showed selective and significant (p<0.05) improvement on the memory subscale of the Dementia Rating Scale. There was also a trend toward improvement on a measure of psychomotor speed and attention. There were no group differences in psychiatric status, motor function, or activities of daily living as measured at baseline or end‐point. Adverse effects resulted in premature withdrawal of four patients on donepezil, two for peripheral cholinergic effects and one for increased parkinsonism. Side effects were associated with dosage increases.

Conclusion

Donepezil has a beneficial effect on memory and may improve other cognitive deficits in patients with PD and cognitive impairment. However, variable tolerability in our sample underscores the need for careful monitoring when prescribing donepezil to patients with PD, especially with dosage increases. Copyright © 2004 John Wiley & Sons, Ltd.

📜 SIMILAR VOLUMES

Cognitive impairment in nondemented Park

Cognitive impairment in nondemented Parkinson's disease

✍ Paolo Barone; Dag Aarsland; David Burn; Murat Emre; Jaime Kulisevsky; Daniel Wei 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 165 KB 👁 1 views

## Abstract A substantial percentage of patients with newly diagnosed Parkinson's disease without dementia are reported to be affected by cognitive impairment (CI). In practice, however, CI is underrecognized, as the signs may not be apparent in early‐stage disease and many routine assessment tools

Twice-daily, low-dose pramipexole in ear

Twice-daily, low-dose pramipexole in early Parkinson's disease: A randomized, placebo-controlled trial

✍ Karl Kieburtz; The Parkinson Study Group PramiBID Investigators 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB 👁 1 views

## Abstract To compare the safety and efficacy of low dosages of pramipexole given twice daily (bid) in early Parkinson's disease (PD) with those of a standard 3 times daily (tid) regimen in a randomized, double‐blind, placebo controlled trial involving 311 early PD patients not receiving dopaminer

Controlled study of decision-making and

Controlled study of decision-making and cognitive impairment in Parkinson's disease

✍ Javier Pagonabarraga; Carmen García-Sánchez; Gisela Llebaria; Berta Pascual-Seda 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 1 views

## Abstract Impulse control disorders (ICD) related to reward‐processing dysfunction have been reported in Parkinson's disease (PD). The relationship between clinical markers of limbic dysfunction with demographic variables and cognitive status of PD is incompletely known. Our objective was to furt

SB-742457 and donepezil in Alzheimer dis

SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study

✍ Gareth Maher-Edwards; Ruth Dixon; Jackie Hunter; Michael Gold; Gillian Hopton; G 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB

## Objective: To estimate the treatment effects of sb-742457 and donepezil in alzheimer disease (ad) in a contemporary clinical trial. ## Method: Randomized, controlled, parallel-group, exploratory study with a 4-week, single-blind, placebo run-in phase and 24-week, double-blind treatment phase.

MRI and cognitive impairment in Parkinso

MRI and cognitive impairment in Parkinson's disease

✍ Naroa Ibarretxe-Bilbao; Eduardo Tolosa; Carme Junque; Maria-Jose Marti 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 1 views

## Abstract Patients with Parkinson's disease (PD) may present impairment in cognitive functions even at early stages of the disease. When compared with the general population, their risk of dementia is five to six times higher. Recent investigations using structural MRI have shown that dementia in

Cognitive impairment and dementia in Par

Cognitive impairment and dementia in Parkinson's disease

✍ Karen Marder 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 1 views

## Abstract Over the last decade, the importance of cognitive impairment and dementia in Parkinson's disease (PDD) has been increasingly recognized. Investigators have proposed criteria for PD dementia, and mild cognitive impairment. Risk profiles associated with the development of dementia based o